<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Carefusion Corporation</title>
	<atom:link href="http://www.stockbloghub.com/tag/carefusion-corporation/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Tue, 22 May 2012 18:53:06 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(OMCL) Omnicell Analyst Reaffirms Shares at Neutral</title>
		<link>http://www.stockbloghub.com/2011/12/14/omcl-omnicell-analyst-reaffirms-shares-at-neutral/87973</link>
		<comments>http://www.stockbloghub.com/2011/12/14/omcl-omnicell-analyst-reaffirms-shares-at-neutral/87973#comments</comments>
		<pubDate>Wed, 14 Dec 2011 20:11:18 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Computer Based Systems]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>
		<category><![CDATA[OMCL]]></category>
		<category><![CDATA[Omnicell Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87973</guid>
		<description><![CDATA[We recently reiterated our Neutral recommendation on Omnicell (OMCL) with a target price of $17.00. Omnicell reported adjusted EPS of 9 cents in the third quarter of fiscal 2011, beating the Zacks Consensus Estimate by a penny and the year-ago quarter EPS of 4 cents. Revenues in the reported quarter increased 5.6% year over year to $64.4 million and surpassed the Zacks Consensus Estimate of $63 million. The company primarily operates in the niche automated medication distribution industry and stands to benefit from favorable demographic trends, regulatory environments, and the lack of nursing staff. As the information technology market is growing in leaps and bounds with increasing investment by healthcare industries and gradual modernization of the healthcare system, the demand for automated healthcare management systems has also been on the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/14/omcl-omnicell-analyst-reaffirms-shares-at-neutral/87973/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health Analyst Maintains Outperform on Shares</title>
		<link>http://www.stockbloghub.com/2011/12/07/cah-cardinal-health-analyst-maintains-outperform-on-shares/88134</link>
		<comments>http://www.stockbloghub.com/2011/12/07/cah-cardinal-health-analyst-maintains-outperform-on-shares/88134#comments</comments>
		<pubDate>Wed, 07 Dec 2011 17:53:10 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health Inc.]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88134</guid>
		<description><![CDATA[We reiterate our Outperform rating on Cardinal Health (CAH). Its first-quarter fiscal 2012 (ended September 30) adjusted earnings per share of 73 cents beat the Zacks Consensus Estimate of 72 cents. Earnings from continuing operations (as reported) dropped about 19% year over year reflecting a previous-year gain from the sale of CareFusion (CFN) shares. Sales for the first quarter rose 10% year over year to $26.8 billion, exceeding the Zacks Consensus Estimate of $26.3 billion. Sales were boosted by growth across the board, notably, buoyancy in the larger Pharmaceutical segment. Revenues from the Pharmaceutical segment spiked 10% year over year in the quarter. Acquisitions contributed to growth as did organic growth from pre-existing clients. Sales from the smaller Medical segment climbed 10%, driven by higher sales to existing and net ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/07/cah-cardinal-health-analyst-maintains-outperform-on-shares/88134/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OMCL) Omnicell&#8217;s G4 Platform Reaches China</title>
		<link>http://www.stockbloghub.com/2011/11/30/omcl-omnicells-g4-platform-reaches-china/87704</link>
		<comments>http://www.stockbloghub.com/2011/11/30/omcl-omnicells-g4-platform-reaches-china/87704#comments</comments>
		<pubDate>Wed, 30 Nov 2011 19:57:39 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Computer Based Systems]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[Gartner Inc.]]></category>
		<category><![CDATA[IT]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>
		<category><![CDATA[OMCL]]></category>
		<category><![CDATA[Omnicell Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87704</guid>
		<description><![CDATA[Recently, Omnicell (OMCL) announced the launch of Mandarin-language versions of its G4 platform for clinical use in China. Following the launch of G4 medication automation platform in English-speaking markets earlier this year, the language conversion of medication cabinets will enable Chinese hospitals to utilize all the advanced operational improvements of G4. The latest move on the company’s part is consistent with its strategy of further expanding in the international market. In China, this system was first implemented at Peking Union Medical College Hospital (PUMCH). A recently completed multi-month pilot study at PUMCH showed that the Omnicell ADCs on Mandarin-language conserve workforce for locating medications by nearly two hours per day. Additionally, Omnicell announced a partnership with China Resources Beijing Pharmaceutical Co. Ltd., which is a subsidiary of China Resources Pharmaceutical ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/30/omcl-omnicells-g4-platform-reaches-china/87704/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OMCL) Omnicell Beats Estimates</title>
		<link>http://www.stockbloghub.com/2011/11/04/omcl-omnicell-beats-estimates/86102</link>
		<comments>http://www.stockbloghub.com/2011/11/04/omcl-omnicell-beats-estimates/86102#comments</comments>
		<pubDate>Fri, 04 Nov 2011 18:57:59 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Computer Based Systems]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health Inc.]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>
		<category><![CDATA[OMCL]]></category>
		<category><![CDATA[Omnicell Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=86102</guid>
		<description><![CDATA[Omnicell Inc. (OMCL) reported EPS of 9 cents during the second quarter of fiscal 2011, beating both the Zacks Consensus Estimate of 8 cents and the year-ago quarter EPS of 4 cents. Reported earnings shot up 125% on a year-over-year basis primarily due to the reduction in effective tax rate from 60% in the year-ago quarter to 35% in the reported quarter. Revenues in the reported quarter increased 5.6% year over year to $64.4 million and surpassed the Zacks Consensus Estimate of $63 million. Product revenue, contributing 77.3% of revenues, increased 15.0% to $49.7 million in the quarter while the same from Services and Others (contributing the rest), witnessed an upside of 12.3%. Cost of Product sales were up 13.6% to $22.4 million in the quarter. However, cost of Services ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/04/omcl-omnicell-beats-estimates/86102/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OMCL) Omnicell Analyst Maintains Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2011/09/20/omcl-omnicell-analyst-maintains-neutral-on-shares/83310</link>
		<comments>http://www.stockbloghub.com/2011/09/20/omcl-omnicell-analyst-maintains-neutral-on-shares/83310#comments</comments>
		<pubDate>Tue, 20 Sep 2011 20:17:32 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Computer Based Systems]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health Inc.]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>
		<category><![CDATA[OMCL]]></category>
		<category><![CDATA[Omnicell Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83310</guid>
		<description><![CDATA[We recently reiterated our Neutral recommendation on Omnicell (OMCL) with a target price of $16.00. Omnicell reported an adjusted EPS of 8 cents in the second quarter of fiscal 2011, beating both the Zacks Consensus Estimate and the year-ago quarter’s EPS of 6 cents. Total revenue for the second quarter was $61.0 million, up 6.6% year over year and surpassed the Zacks Consensus Estimate of $60.0 million. Product revenue, contributing 75.8% of Omnicell’s top line, increased 8.5% to $46.2 million in the quarter while revenues from Services and Others (contributing the rest), witnessed a marginal upside of 1.4%. The company operates in the niche automated medication distribution industry and stands to benefit from favorable demographic trends, regulatory environments, and the lack of nursing staff. As the information technology market is ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/20/omcl-omnicell-analyst-maintains-neutral-on-shares/83310/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AOL) Company News for August 10, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/08/10/aol-company-news-for-august-10-2011-corporate-summary/81050</link>
		<comments>http://www.stockbloghub.com/2011/08/10/aol-company-news-for-august-10-2011-corporate-summary/81050#comments</comments>
		<pubDate>Wed, 10 Aug 2011 20:40:24 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Internet Information Providers]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[AOL]]></category>
		<category><![CDATA[Aol Incorporated]]></category>
		<category><![CDATA[ATP Oil & Gas Corporation]]></category>
		<category><![CDATA[ATPG]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CBS]]></category>
		<category><![CDATA[CBS Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[GEOI]]></category>
		<category><![CDATA[GeoResources Inc]]></category>
		<category><![CDATA[Lance Inc.]]></category>
		<category><![CDATA[LNCE]]></category>
		<category><![CDATA[ReneSola Limited]]></category>
		<category><![CDATA[Sempra Energy]]></category>
		<category><![CDATA[SOL]]></category>
		<category><![CDATA[SRE]]></category>
		<category><![CDATA[Stereotaxis Inc]]></category>
		<category><![CDATA[STXS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=81050</guid>
		<description><![CDATA[•    AOL (NYSE:AOL) reported a loss Q2 EPS of $0.11, against the Zacks Consensus Estimate of a profit of $0.02 per share. Revenues for the quarter declined by 8% to $542.2 million•    Snyder&#8217;s-Lance (NASDAQ:LNCE) posted Q2 EPS of $0.16, ex-items, missing the Zacks Consensus Estimate of $0.18 per share. Revenues for the quarter increased by 75.7% year-over-year to $413.0 million •    ReneSola (NYSE:SOL) posted Q2 EPS of $0.02, missing consensus estimates of $0.16 per share. Revenues declined 1.8% year-over-year to $249.3 million against consensus estimates of $147.6 million •    Sempra Energy (NYSE:SRE) reported adjusted Q2 EPS of $0.97, which came in lower than the Zacks Consensus Estimate of $1.00 per share. Revenues for the quarter increased 21% year-over-year to $2.42 billion •    ATP Oil &#38; Gas (NASDAQ:ATPG) posted a Q2 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/10/aol-company-news-for-august-10-2011-corporate-summary/81050/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CFN) CareFusion Buying Rowa for $150 Million</title>
		<link>http://www.stockbloghub.com/2011/07/12/cfn-carefusion-buying-rowa-for-150-million/78859</link>
		<comments>http://www.stockbloghub.com/2011/07/12/cfn-carefusion-buying-rowa-for-150-million/78859#comments</comments>
		<pubDate>Tue, 12 Jul 2011 16:57:24 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International Inc]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78859</guid>
		<description><![CDATA[Medical technology company CareFusion Corporation (CFN) recently made a deal to buy German medication storage systems maker Rowa GmbH for roughly $150 million. Rowa, which has customers in 30 countries, specializes in high-speed robotic medication storage and retrieval systems for retail and hospital pharmacies. The company has deployed more than 3,500 automation systems in retail and hospital pharmacies and added 500 new customers last year. In addition to its stronghold in Germany, Rowa has operations in Italy, the Netherlands, Denmark and Sweden. The company’s installations climbed 9% in 2010 and it expanded product sales into Australia, Canada and other new markets during the year. Rowa&#8217;s automated systems, which are used to store and retrieve packaged pharmaceutical inventories, are geared to cut costs and improve workflow. Its products and technologiesare complementary ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/12/cfn-carefusion-buying-rowa-for-150-million/78859/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OMCL) Omnicell&#8217;s Electronic Health Record Wins Certification</title>
		<link>http://www.stockbloghub.com/2011/06/22/omcl-omnicells-electronic-health-record-wins-certification/77065</link>
		<comments>http://www.stockbloghub.com/2011/06/22/omcl-omnicells-electronic-health-record-wins-certification/77065#comments</comments>
		<pubDate>Wed, 22 Jun 2011 17:01:42 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Computer Based Systems]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health Inc.]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>
		<category><![CDATA[OMCL]]></category>
		<category><![CDATA[Omnicell Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77065</guid>
		<description><![CDATA[Omnicell, Inc. (OMCL), a leading developer and marketer of end-to-end automation solutions for the medication-use process, recently announced that its newly launched G4 platform received the ONC-ATCB certification as a Modular Electronic Health Record (“EHR&#8221;). Omnicell became the first hospital pharmacy automation company to achieve this certification and the company intends to support its clients to qualify for federal funding incentives under the American Recovery and Reinvestment Act (“ARRA”). The Centers for Medicare &#38; Medicaid Services, on May 19, 2011, made the first round of payments totaling $75 million to providers who successfully fulfilled the Stage One requirements for Meaningful Use.  The fulfillment of Meaningful Use criteria is essential for securing federal incentives. EHR automates the process of writing prescriptions and enables the physicians to send prescriptions directly to a ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/22/omcl-omnicells-electronic-health-record-wins-certification/77065/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OMCL) Omnicell  Earns Second Consecutive Best in Klas Award</title>
		<link>http://www.stockbloghub.com/2011/06/19/omcl-omnicell-earns-second-consecutive-best-in-klas-award/76681</link>
		<comments>http://www.stockbloghub.com/2011/06/19/omcl-omnicell-earns-second-consecutive-best-in-klas-award/76681#comments</comments>
		<pubDate>Sun, 19 Jun 2011 17:33:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Computer Based Systems]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health Inc.]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>
		<category><![CDATA[OMCL]]></category>
		<category><![CDATA[Omnicell Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76681</guid>
		<description><![CDATA[Omnicell (OMCL), recently announced that it has received recognition for its OmniRx automated dispensing system from leading research firm, KLAS for the second consecutive year.  Along with the  2011 “Best in KLAS&#8221; award for Automated Medication Dispensing Units for large hospitals with more than 200 beds category, Omnicell was also  recognized  as the Category Leader for OmniRx for hospitals under 200 beds. This is the sixth consecutive year that OmniRx has received this KLAS ranking as Category Leader. Omnicell, for the second consecutive year, was adjudged Category Leader for Pharmacy Automation: Medication Carousels for its WorkflowRx Carousel and Category Leader in the new Anesthesia Cabinets award category for Omnicell&#8217;s Anesthesia Workstation. Moreover, Omnicell&#8217;s OmniLinkRx received the Category Leader Distinction for Medication Order Management Systems in Klas’ Software &#38; Professional Services ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/19/omcl-omnicell-earns-second-consecutive-best-in-klas-award/76681/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health Third Quarter 2011 Earnings Preview</title>
		<link>http://www.stockbloghub.com/2011/04/27/cah-cardinal-health-third-quarter-2011-earnings-preview/72565</link>
		<comments>http://www.stockbloghub.com/2011/04/27/cah-cardinal-health-third-quarter-2011-earnings-preview/72565#comments</comments>
		<pubDate>Wed, 27 Apr 2011 17:28:55 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health Inc.]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=72565</guid>
		<description><![CDATA[Cardinal Health (CAH) is slated to report its third-quarter fiscal 2011 (ending March) results on Thursday, April 28. The company expects earnings per share in the range of $2.54 to $2.60 for fiscal 2011. The current Zacks Consensus Estimate for revenues and earnings for the third quarter are $25.6 billion and 69 cents per share, respectively. Second Quarter Recap Cardinal Health reported second-quarter fiscal 2011 adjusted earnings per share of 69 cents, beating the Zacks Consensus Estimate of 61 cents and surpassing the year-ago results of 57 cents. Total sales were up 2% year over year to $25.4 billion, beating the Zacks Consensus Estimate. Higher sales from the core Pharmaceutical division were partly offset by a modest decline in the Medical segment. Revenues from the larger Pharmaceutical segment moved up ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/27/cah-cardinal-health-third-quarter-2011-earnings-preview/72565/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health Gets Antitrust Clearance</title>
		<link>http://www.stockbloghub.com/2010/12/20/cah-cardinal-health-gets-antitrust-clearance/62814</link>
		<comments>http://www.stockbloghub.com/2010/12/20/cah-cardinal-health-gets-antitrust-clearance/62814#comments</comments>
		<pubDate>Mon, 20 Dec 2010 20:27:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=62814</guid>
		<description><![CDATA[Cardinal Health (CAH) recently announced that antitrust regulators had cleared its $1.3 billion takeover of Kinray, a leading pharma distributor with a presence in the New York metropolitan area. In this regard, the Federal Trade Commission (“FTC”) had approved early termination of waiting period, under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, for the planned takeover. The cash deal to acquire Kinray will enhance Cardinal’s capability to cater to retail independent pharmacies in the northeastern U.S. markets. Cardinal expects to shortly close the deal. The company earlier anticipated that the transaction will be neutral to slightly accretive to its fiscal 2011 adjusted earnings, contingent upon the time of the deal closure. Cardinal projects accretion of not less than 12 cents in adjusted earning per share from continuing operations in fiscal ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/12/20/cah-cardinal-health-gets-antitrust-clearance/62814/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health Announces Buy of Kinray</title>
		<link>http://www.stockbloghub.com/2010/12/19/cah-cardinal-health-announces-buy-of-kinray/60379</link>
		<comments>http://www.stockbloghub.com/2010/12/19/cah-cardinal-health-announces-buy-of-kinray/60379#comments</comments>
		<pubDate>Sun, 19 Dec 2010 23:25:20 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=60379</guid>
		<description><![CDATA[Cardinal Health (CAH) recently announced plans to purchase Kinray Inc., a leading pharma distributor with a presence in the New York metropolitan area. The cash deal will enhance Cardinal’s capability to cater to retail independent pharmacies in the northeastern U.S. markets. Cardinal expects to close the deal by the end of the current calendar year, or early-2011, depending on regulatory approval and closing conditions. The company anticipates that the transaction will be neutral to slightly accretive to its fiscal 2011 adjusted earnings, contingent upon the time of the deal closure. Cardinal projects accretion of not less than 12 cents in adjusted earning per share from continuing operations in fiscal 2012, after taking into account the effect of amortization of intangibles. Kinray is one of the largest privately held distributors of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/12/19/cah-cardinal-health-announces-buy-of-kinray/60379/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health Prepares for Coming Flu Season</title>
		<link>http://www.stockbloghub.com/2010/10/03/cah-cardinal-health-prepares-for-coming-flu-season/53709</link>
		<comments>http://www.stockbloghub.com/2010/10/03/cah-cardinal-health-prepares-for-coming-flu-season/53709#comments</comments>
		<pubDate>Mon, 04 Oct 2010 05:13:42 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=53709</guid>
		<description><![CDATA[Cardinal Health (CAH) is taking necessary steps to maintain the supply of influenza vaccines during the forthcoming 2010-2011 flu season. For the first time, the Advisory Committee on Immunization Practices (ACIP) has been asking everyone over 6 months of age to get a flu vaccine. The company is of the opinion that the supplies are sufficient to meet the demand as a result of which everybody will have access to the vaccine. There is no need of prioritization. The flu season of last year resulted in more than 270,000 hospitalizations and 12,000 deaths. However, the upcoming season should not be very severe due to the immunity developed from the last infection and availability of the flu vaccine. Moreover, the flu vaccine will target the H1N1 strain in addition to the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/10/03/cah-cardinal-health-prepares-for-coming-flu-season/53709/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health Sells Remaining CareFusion Shares</title>
		<link>http://www.stockbloghub.com/2010/09/19/cah-cardinal-health-sells-remaining-carefusion-shares/52054</link>
		<comments>http://www.stockbloghub.com/2010/09/19/cah-cardinal-health-sells-remaining-carefusion-shares/52054#comments</comments>
		<pubDate>Sun, 19 Sep 2010 17:57:49 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=52054</guid>
		<description><![CDATA[Cardinal Health (CAH), a leading distributor of pharmaceuticals and medical supplies, recently sold off the remaining 30.5 million shares of CareFusion Corporation (CFN) for $705.9 million. CareFusion, a San Diego-based vendor for medical equipment and infection control supplies, was spun off from Cardinal Health in 2009. As per the spin-off arrangement, Cardinal Health distributed 0.5 shares of CareFusion common stock for each share of its stock that was outstanding. It retained about 19% of the shares in CareFusion at the time of the distribution. Under the terms of the agreement Cardinal Health was required to dispose of its equity holdings in CareFusion within five years of the distribution (by August 31, 2014). The agreement authorized Cardinal to dispose of its shares through open-market sales, private sales or a combination of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/09/19/cah-cardinal-health-sells-remaining-carefusion-shares/52054/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health Earnings Scorecard</title>
		<link>http://www.stockbloghub.com/2010/08/11/cah-cardinal-health-earnings-scorecard/47655</link>
		<comments>http://www.stockbloghub.com/2010/08/11/cah-cardinal-health-earnings-scorecard/47655#comments</comments>
		<pubDate>Thu, 12 Aug 2010 05:16:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=47655</guid>
		<description><![CDATA[Cardinal Health (CAH), one of the largest distributors of pharmaceuticals and medical supplies, recently reported earnings for fourth-quarter of fiscal year 2010, which beat the Zacks Consensus Estimate by a penny. Revenues grew by a mere 0.5% year over year to $22.3 billion. Pharmaceutical revenues were essentially flat year over year as higher sales to non-bulk customers were offset by lower bulk customer revenues. On a positive note, the company’s generic pharmaceutical business posted a 10% revenue growth in the quarter. The spin-off of CareFusion (CFN) has enabled Cardinal to increase focus on its core healthcare supply chain business. Moreover, Cardinal recently acquired privately held specialty pharmaceutical services company Healthcare Solutions Holding for $667 million. The acquisition has expanded its foothold in the fast-growing specialty pharmaceutical services segment. Agreement – ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/11/cah-cardinal-health-earnings-scorecard/47655/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health&#8217;s Report Beats Expectations by a Penny</title>
		<link>http://www.stockbloghub.com/2010/08/06/cah-cardinal-healths-report-beats-expectations-by-a-penny/46854</link>
		<comments>http://www.stockbloghub.com/2010/08/06/cah-cardinal-healths-report-beats-expectations-by-a-penny/46854#comments</comments>
		<pubDate>Fri, 06 Aug 2010 16:56:23 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[Coventry Health Care Inc.]]></category>
		<category><![CDATA[CVH]]></category>
		<category><![CDATA[CVS]]></category>
		<category><![CDATA[CVS Caremark Corporation]]></category>
		<category><![CDATA[WAG]]></category>
		<category><![CDATA[Walgreen Company]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=46854</guid>
		<description><![CDATA[Cardinal Health (CAH) reported fourth-quarter and fiscal 2010 adjusted (excluding one-time expenses) earnings per share of 50 cents and $2.22 respectively, exceeding the Zacks Consensus Estimates of 49 cents and $2.21, respectively, but below the year-ago results of 63 cents and $2.26, respectively. Revenues Total revenue was $24.5 billion in the fourth quarter, up by a mere 0.5% year over year, and $98.5 billion in fiscal 2010, up 3%. Reported results were marginally below the Zacks Consensus Estimates of $24.6 billion and $98.7 billion for the fourth quarter and fiscal year, respectively. Segment-wise Revenue The Pharmaceutical segment reported fourth-quarter revenue of $22.3 billion, up a nominal 0.2%. Sales to non-bulk customers were $11.5 billion, up 3% year over year, while sales to bulk customers were $10.8 billion, down 3%. Generic ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/06/cah-cardinal-healths-report-beats-expectations-by-a-penny/46854/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health Earnings Preview</title>
		<link>http://www.stockbloghub.com/2010/08/02/cah-cardinal-health-earnings-preview/46047</link>
		<comments>http://www.stockbloghub.com/2010/08/02/cah-cardinal-health-earnings-preview/46047#comments</comments>
		<pubDate>Tue, 03 Aug 2010 04:23:56 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[CVS]]></category>
		<category><![CDATA[CVS Caremark Corporation]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[WAG]]></category>
		<category><![CDATA[Walgreen Company]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=46047</guid>
		<description><![CDATA[Cardinal Health (CAH) is slated to report fourth-quarter and fiscal 2010 (ending June 30, 2010) results on Thursday, August 5, 2010. The company earlier issued earnings per share guidance in the range of $2.15 to $2.20 for fiscal 2010. The current Zacks Consensus Estimate for the fourth quarter is 49 cents, representing an estimated 43.2% year over year decline. Third Quarter Recap Cardinal Health reported third-quarter fiscal 2010 adjusted (excluding one-time gain on sale of CareFusion stock) earnings per share of 61 cents, outperforming the Zacks Consensus Estimate of 57 cents. Total sales increased 1% year over year to $24.3 billion. The company experienced moderate growth in both its business segments, Pharmaceutical (comprising bulk and non bulk customers) and Medical. Revenues for the much larger Pharmaceutical segment increased 0.5% year ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/02/cah-cardinal-health-earnings-preview/46047/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HSP) Hospira Second Quarter 2010 Earnings Preview</title>
		<link>http://www.stockbloghub.com/2010/08/02/hsp-hospira-second-quarter-2010-earnings-preview/44895</link>
		<comments>http://www.stockbloghub.com/2010/08/02/hsp-hospira-second-quarter-2010-earnings-preview/44895#comments</comments>
		<pubDate>Mon, 02 Aug 2010 21:52:31 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International Inc]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[DRRX]]></category>
		<category><![CDATA[Durect Corporation]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Hospira Inc.]]></category>
		<category><![CDATA[HSP]]></category>
		<category><![CDATA[MAXIMUS Inc.]]></category>
		<category><![CDATA[MMS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=44895</guid>
		<description><![CDATA[Hospira Inc. (HSP) is scheduled to report its second quarter 2010 results on Wednesday, July 28, before the opening bell. The Zacks Consensus Estimate for the quarter is earnings of 79 cents per share (with an upside of 2.53%), compared with earnings of 73 cents per share in the year-earlier period. The Zacks Consensus Estimate for second-quarter revenue is $1,006 million as against $957 million reported in the year-ago quarter. First-Quarter Recap Hospira Inc.’s first-quarter fiscal 2010 earnings (excluding special items) of 94 cents per share handsomely beat the Zacks Consensus Estimate of 72 cents and the year-ago earnings of 60 cents. On a reported basis, the company earned 84 cents per share, down 18.4% from the year-ago earnings. Revenues for the quarter climbed 17.2% year over year to $1 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/02/hsp-hospira-second-quarter-2010-earnings-preview/44895/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CFN) CareFusion Decides to Acquire Medegen for $225 Million</title>
		<link>http://www.stockbloghub.com/2010/04/07/cfn-carefusion-decides-to-acquire-medegen-for-225-million/33028</link>
		<comments>http://www.stockbloghub.com/2010/04/07/cfn-carefusion-decides-to-acquire-medegen-for-225-million/33028#comments</comments>
		<pubDate>Thu, 08 Apr 2010 00:24:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=33028</guid>
		<description><![CDATA[CareFusion Corporation (CFN) has decided to acquire Medegen for $225 million in cash. CareFusion expects the acquisition to be neutral to the adjusted earnings per share in the first year of operations and increasingly accretive thereafter. The acquisition is expected to be completed by June 30, 2010. Medegen is a leading innovator in infusion therapy which consists of clinically differentiated needle-less access valves and administration sets that deliver intravenous (IV) medication to patients. We believe Medegen would be a ‘strategic fit’ for CareFusion and it will be able to fully integrate Medegen’s operations. Both CareFusion and Medegen have matching infusion product lines and R&#38;D investments. Furthermore, CareFusion’s products are also backed by clinical evidence and differentiation. CareFusion is a medical technology company formed by the spin-off of the Clinical and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/07/cfn-carefusion-decides-to-acquire-medegen-for-225-million/33028/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CFN) CareFusion Corporation Beats Consensus Estimates</title>
		<link>http://www.stockbloghub.com/2010/02/10/cfn-carefusion-corporation-beats-consensus-estimates/27655</link>
		<comments>http://www.stockbloghub.com/2010/02/10/cfn-carefusion-corporation-beats-consensus-estimates/27655#comments</comments>
		<pubDate>Thu, 11 Feb 2010 00:21:08 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=27655</guid>
		<description><![CDATA[CareFusion Corporation (CFN) recently reported second quarter fiscal 2010 earnings per share of 39 cents, marginally beating the Zacks Consensus Estimate of 38 cents, but lower than the year-ago earnings of 50 cents. Total revenues in the second quarter increased 5% year over year to $1.0 billion. Growth was witnessed across all business segments. Critical Care Technologies revenues increased 1% year over year to $682 million as a result of higher demand for the company’s respiratory business. Medical Technologies and Services revenues increased 15% year over year to $337 million. Growth was driven by higher sales from the company’s International Surgical Products and Interventional Specialties businesses. CareFusion reported a contraction in margins in the second quarter. Adjusted gross margin declined 200 basis points (bps) year over year to 46.9%. Adjusted ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/10/cfn-carefusion-corporation-beats-consensus-estimates/27655/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health Upgraded to Outperform</title>
		<link>http://www.stockbloghub.com/2010/02/10/cah-cardinal-health-upgraded-to-outperform/27680</link>
		<comments>http://www.stockbloghub.com/2010/02/10/cah-cardinal-health-upgraded-to-outperform/27680#comments</comments>
		<pubDate>Wed, 10 Feb 2010 21:17:07 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=27680</guid>
		<description><![CDATA[We have recently upgraded Cardinal Health Inc. (CAH) to “Outperform&#8221; with a target price of $37 based on approximately 15.7x our fiscal 2011 EPS estimate of $2.36. Cardinal Health reported second quarter fiscal 2010 earnings per share of 57 cents, beating the Zacks Consensus Estimate of 46 cents and the year-ago earnings of 51 cents. Total sales increased 3% year over year to $24.9 billion, fueled by growth across all business segments. Pharmaceutical segment revenues increased 3% year over year to $22.7 billion. Growth was primarily fueled by higher sales to existing pharmaceutical distribution customers. Sales to bulk customers declined 1% year over year to $11.0 billion. Sales to non-bulk customers increased 7% year over year to $11.7 billion. Medical segment revenues increased 9% year over year to $2.2 billion. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/10/cah-cardinal-health-upgraded-to-outperform/27680/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(FOSL) Flies in the Ointment</title>
		<link>http://www.stockbloghub.com/2010/02/02/fosl-flies-in-the-ointment/26729</link>
		<comments>http://www.stockbloghub.com/2010/02/02/fosl-flies-in-the-ointment/26729#comments</comments>
		<pubDate>Tue, 02 Feb 2010 18:18:32 +0000</pubDate>
		<dc:creator>Wax</dc:creator>
				<category><![CDATA[Consumer Goods]]></category>
		<category><![CDATA[Recreational Goods Other]]></category>
		<category><![CDATA[Bally Technologies]]></category>
		<category><![CDATA[BYI]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[FOSL]]></category>
		<category><![CDATA[Fossil Inc.]]></category>
		<category><![CDATA[iGate Corporation]]></category>
		<category><![CDATA[IGTE]]></category>
		<category><![CDATA[SNA]]></category>
		<category><![CDATA[Snap-on Inc.]]></category>
		<category><![CDATA[STE]]></category>
		<category><![CDATA[Steris Corporation]]></category>
		<category><![CDATA[Technitrol Inc.]]></category>
		<category><![CDATA[TNL]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=26729</guid>
		<description><![CDATA[We had several e-mails over the recent holidays asking what we did with research for companies we had decided not to pursue and would we consider sharing that research with others. Unlike most folks, we do not use stock screens. We see something on the web, or read something in a periodical, or are asked about a particular industry sector and we take a look. Regardless of how we come up with the name of a company, all of our research begins with a Raw Value worksheet. From there, a determination is made if additional research is warranted at that time. If it is, we continue with our research, often going back 10 years of more, in an effort to determine reasonable financial averages. If it isn&#8217;t the related worksheets ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/02/fosl-flies-in-the-ointment/26729/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CFN) CareFusion Corporation Enters Agreement with Masimo</title>
		<link>http://www.stockbloghub.com/2009/11/14/masi-carefusion-corporation-enters-agreement-with-masimo/20535</link>
		<comments>http://www.stockbloghub.com/2009/11/14/masi-carefusion-corporation-enters-agreement-with-masimo/20535#comments</comments>
		<pubDate>Sat, 14 Nov 2009 22:12:01 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health Inc.]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[MASI]]></category>
		<category><![CDATA[Masimo Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20535</guid>
		<description><![CDATA[CareFusion Corp. (CFN) entered into a multi-year technology licensing agreement with Masimo Corp. (MASI) regarding the use of Masimo Rainbow SET Pulse CO-Oximetry technology in CareFusion infusion and respiratory products, which are presently under development. The agreement enables CareFusion’s future infusion and respiratory products to non-invasively and continuously measure multiple blood constituents to more accurately assess dyshemoglobins affecting oxygenation, predict fluid responsiveness, and provide earlier identification of respiratory compromise. CareFusion’s ventilators and infusion pumps facilitate earlier detection, diagnosis and treatment of potentially life-threatening conditions by accessing total hemoglobin (SpHb), oxygen content (SpOC), carboxyhemoglobin (SpCO), methemoglobin (SpMet), and PVI for fluid responsiveness, in addition to oxyhemoglobin (SpO2), perfusion index (PI), and pulse rate. CareFusion is a medical technology company formed recently by the spin-off of the Clinical and Medical Products business ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/14/masi-carefusion-corporation-enters-agreement-with-masimo/20535/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

